Formulation Development Evaluation and Optimization of Orodispersible Tablets of Frovatriptan for The Treatment of Migraine

The aim of present research work is to formulate and evaluate Oral dispersible tablets of frovatriptan using various diluents and superdisintegrants and to optimize the formulation. Frovatriptan is a triptan drug  used for the treatment of migraine headaches. The drug excipient compatibility study was done and  no interactions were found, DSC & XRD studies were carried out. The tablets were formulated by direct compression method using Spray dried lactose, Manito, Microcrystalline cellulose (MCC), Starch as diluents and Crospovidone, Cross-Carmel lose sodium, Sodium starch glycol ate as superdisintegrants. The pre-compression parameters like bulk density, tapped density, Carr’s Index, Haunters ratio and angle of repose were determined and all the formulations were found to be within IP limits. The post compression parameters like the hardness, thickness, friability, weight variation, and disintegrating time, wetting time, water absorption ratio and drug content for all the formulations were carried out and results were found to be as per USP limits. In-vitro drug release and kinetics studies were carried out for all the formulations, of those the formulation F33 containing Cross providing (5%) and mannitol as diluent, has shown better release and follows first order kinetics. The formulations were optimized by 22 factorial design and the ANOVA study was carried out and normal plot, half normal plot and overlay plot were plotted. The tablets were stored at 40±2ËšC/75 ± 5% RH for three months to assess the stability of optimized formulation.